Diamond Equity Issues Pessimistic Forecast for BHST Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at Diamond Equity cut their Q3 2025 earnings per share estimates for shares of BioHarvest Sciences in a research note issued to investors on Wednesday, August 13th. Diamond Equity analyst H. Diamond now expects that the company will post earnings of ($0.17) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences’ Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.06) EPS and Q2 2026 earnings at ($0.03) EPS.

BioHarvest Sciences (NASDAQ:BHST) last released its earnings results on Monday, August 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). The firm had revenue of $8.52 million during the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%.

Separately, Craig Hallum started coverage on BioHarvest Sciences in a research note on Monday, May 5th. They issued a “buy” rating and a $15.00 target price on the stock.

BioHarvest Sciences Stock Performance

NASDAQ BHST opened at $9.32 on Friday. The stock has a market capitalization of $153.03 million, a price-to-earnings ratio of -13.31 and a beta of 0.68. The stock’s 50 day moving average price is $7.41 and its two-hundred day moving average price is $6.46. BioHarvest Sciences has a 52 week low of $4.66 and a 52 week high of $9.90.

Institutional Investors Weigh In On BioHarvest Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Magnus Financial Group LLC raised its stake in shares of BioHarvest Sciences by 105.0% during the 1st quarter. Magnus Financial Group LLC now owns 71,733 shares of the company’s stock worth $444,000 after purchasing an additional 36,733 shares in the last quarter. True North Advisors LLC raised its stake in shares of BioHarvest Sciences by 7.6% during the 1st quarter. True North Advisors LLC now owns 44,391 shares of the company’s stock worth $275,000 after purchasing an additional 3,120 shares in the last quarter. Finally, TD Waterhouse Canada Inc. bought a new stake in shares of BioHarvest Sciences during the 4th quarter worth approximately $69,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.